Gyeonggi-do, South Korea

Wonrak Son

This inventor holds 1 USPTO granted patent. Top assignees: Abion Inc., Seoul National University. Active years: 2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Wonrak Son. Retrieved from https://idiyas.com/inventor/wonrak-son

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

% Patents Active = 100.0

Average Co-Inventor Count = 5.0

ph-index = 1


Company Filing History:


Years Active: 2026

Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovations of Wonrak Son

Introduction

Wonrak Son is a notable inventor based in Gyeonggi-do, South Korea. He has made significant contributions to the field of biotechnology, particularly in the development of pharmaceutical compositions.

Latest Patents

Wonrak Son holds a patent for an invention titled "In-Vitro Transcript mRNA and Pharmaceutical Composition Comprising Same." This patent showcases his innovative approach to mRNA technology and its applications in pharmaceuticals. He has 1 patent to his name.

Career Highlights

Throughout his career, Wonrak Son has worked with prestigious institutions, including Seoul National University and Abion Inc. His experience in these organizations has allowed him to advance his research and contribute to significant scientific advancements.

Collaborations

Wonrak Son has collaborated with esteemed colleagues such as Young Key Shin and Jun Young Choi. These partnerships have fostered a collaborative environment that enhances innovation and research outcomes.

Conclusion

Wonrak Son's contributions to biotechnology and his innovative patent reflect his dedication to advancing the field. His work continues to inspire future developments in pharmaceutical technology.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…